Miguel Hernan, D.P.H., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Causality | 11 | 2021 | 1180 | 2.270 |
Why?
|
| Epidemiologic Research Design | 6 | 2016 | 369 | 1.480 |
Why?
|
| Observation | 5 | 2012 | 315 | 1.430 |
Why?
|
| Epidemiologic Studies | 5 | 2016 | 652 | 1.320 |
Why?
|
| Comparative Effectiveness Research | 4 | 2016 | 689 | 0.990 |
Why?
|
| Selection Bias | 5 | 2016 | 365 | 0.900 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2012 | 9596 | 0.680 |
Why?
|
| Parkinson Disease | 6 | 2006 | 2680 | 0.560 |
Why?
|
| Hepatitis B Vaccines | 2 | 2006 | 193 | 0.510 |
Why?
|
| Multiple Sclerosis | 5 | 2006 | 3002 | 0.460 |
Why?
|
| Smoking | 7 | 2008 | 8980 | 0.460 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2015 | 1881 | 0.450 |
Why?
|
| Epidemiologic Methods | 3 | 2009 | 1385 | 0.450 |
Why?
|
| Oseltamivir | 1 | 2011 | 71 | 0.410 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 3149 | 0.390 |
Why?
|
| Water | 1 | 2016 | 1321 | 0.390 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 421 | 0.390 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 1525 | 0.390 |
Why?
|
| Data Interpretation, Statistical | 3 | 2011 | 2729 | 0.380 |
Why?
|
| AIDS Dementia Complex | 2 | 2015 | 147 | 0.380 |
Why?
|
| Tetanus Toxoid | 2 | 2006 | 208 | 0.350 |
Why?
|
| Pneumonia, Bacterial | 1 | 2011 | 315 | 0.330 |
Why?
|
| Coronary Disease | 2 | 2012 | 6150 | 0.300 |
Why?
|
| Pharmacoepidemiology | 1 | 2008 | 321 | 0.280 |
Why?
|
| Leisure Activities | 1 | 2005 | 306 | 0.240 |
Why?
|
| Proportional Hazards Models | 5 | 2011 | 12456 | 0.240 |
Why?
|
| Central Nervous System | 2 | 2015 | 1291 | 0.240 |
Why?
|
| Monoamine Oxidase | 1 | 2002 | 170 | 0.220 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2008 | 1185 | 0.220 |
Why?
|
| Life Expectancy | 1 | 2008 | 1143 | 0.210 |
Why?
|
| Anti-HIV Agents | 3 | 2015 | 4081 | 0.210 |
Why?
|
| HIV Infections | 4 | 2011 | 15784 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 1623 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2009 | 12535 | 0.200 |
Why?
|
| Models, Statistical | 5 | 2011 | 5064 | 0.200 |
Why?
|
| Influenza, Human | 1 | 2011 | 1388 | 0.200 |
Why?
|
| Zidovudine | 1 | 2002 | 605 | 0.190 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2002 | 245 | 0.190 |
Why?
|
| Neural Tube Defects | 1 | 2002 | 247 | 0.190 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2005 | 509 | 0.190 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2000 | 183 | 0.180 |
Why?
|
| HIV-1 | 2 | 2010 | 6838 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2011 | 2802 | 0.170 |
Why?
|
| Coffee | 1 | 2002 | 560 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2011 | 2546 | 0.160 |
Why?
|
| Longitudinal Studies | 3 | 2008 | 13643 | 0.160 |
Why?
|
| Vaccination | 2 | 2006 | 2939 | 0.160 |
Why?
|
| Humans | 38 | 2021 | 715777 | 0.150 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 2316 | 0.140 |
Why?
|
| Body Composition | 1 | 2005 | 2395 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2280 | 0.140 |
Why?
|
| Odds Ratio | 5 | 2008 | 9984 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2021 | 7895 | 0.130 |
Why?
|
| Folic Acid | 1 | 2002 | 1252 | 0.130 |
Why?
|
| Dementia | 1 | 2008 | 2258 | 0.130 |
Why?
|
| Alcoholism | 1 | 2004 | 1859 | 0.130 |
Why?
|
| Time Factors | 7 | 2016 | 40875 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2011 | 23464 | 0.110 |
Why?
|
| Case-Control Studies | 6 | 2006 | 21797 | 0.110 |
Why?
|
| Prospective Studies | 9 | 2011 | 51315 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 5031 | 0.110 |
Why?
|
| Health Status | 1 | 2005 | 4001 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 4352 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 3899 | 0.100 |
Why?
|
| Female | 20 | 2016 | 377204 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6552 | 0.090 |
Why?
|
| Research Design | 3 | 2016 | 5902 | 0.090 |
Why?
|
| Decision Making | 2 | 2016 | 3846 | 0.090 |
Why?
|
| Neoplasms | 1 | 2018 | 20528 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 4378 | 0.090 |
Why?
|
| Male | 17 | 2016 | 350324 | 0.090 |
Why?
|
| Exercise | 1 | 2005 | 5427 | 0.090 |
Why?
|
| Developed Countries | 1 | 2011 | 409 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2013 | 725 | 0.080 |
Why?
|
| Incidence | 5 | 2006 | 20731 | 0.080 |
Why?
|
| Middle Aged | 13 | 2011 | 214639 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 498 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 193 | 0.080 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 257 | 0.080 |
Why?
|
| Progestins | 1 | 2008 | 283 | 0.080 |
Why?
|
| Aging | 1 | 2005 | 8350 | 0.070 |
Why?
|
| Cohort Studies | 6 | 2006 | 40029 | 0.070 |
Why?
|
| Obesity | 1 | 2008 | 12248 | 0.070 |
Why?
|
| Tremor | 1 | 2006 | 154 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14902 | 0.070 |
Why?
|
| Risk Factors | 7 | 2006 | 70866 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2012 | 1511 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2006 | 189 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1207 | 0.070 |
Why?
|
| Aged | 9 | 2011 | 162448 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2005 | 339 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2012 | 1161 | 0.060 |
Why?
|
| Beer | 1 | 2003 | 122 | 0.060 |
Why?
|
| Adult | 10 | 2011 | 212266 | 0.060 |
Why?
|
| United States | 6 | 2013 | 67905 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2006 | 2550 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 14438 | 0.060 |
Why?
|
| Population | 1 | 2003 | 151 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 517 | 0.060 |
Why?
|
| Wine | 1 | 2003 | 162 | 0.060 |
Why?
|
| Europe | 1 | 2010 | 3343 | 0.060 |
Why?
|
| Risk | 2 | 2006 | 9801 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 2150 | 0.060 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2005 | 222 | 0.060 |
Why?
|
| Research Subjects | 1 | 2004 | 248 | 0.060 |
Why?
|
| Acetaminophen | 1 | 2006 | 551 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 1738 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2005 | 652 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 634 | 0.050 |
Why?
|
| Disease Progression | 2 | 2011 | 13215 | 0.050 |
Why?
|
| Estrogens | 1 | 2008 | 1529 | 0.050 |
Why?
|
| California | 1 | 2005 | 1396 | 0.050 |
Why?
|
| Ontario | 1 | 2002 | 366 | 0.050 |
Why?
|
| Viral Load | 1 | 2010 | 3254 | 0.050 |
Why?
|
| Longevity | 1 | 2008 | 1030 | 0.050 |
Why?
|
| Probability | 1 | 2006 | 2487 | 0.050 |
Why?
|
| Anthropometry | 1 | 2005 | 1370 | 0.050 |
Why?
|
| Cause of Death | 1 | 2011 | 3612 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2012 | 2046 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 1709 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8890 | 0.040 |
Why?
|
| Caffeine | 1 | 2003 | 704 | 0.040 |
Why?
|
| Patient Selection | 1 | 2011 | 4293 | 0.040 |
Why?
|
| Disease | 1 | 2004 | 705 | 0.040 |
Why?
|
| Health Surveys | 1 | 2008 | 4036 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 689 | 0.040 |
Why?
|
| Research | 1 | 2004 | 2016 | 0.030 |
Why?
|
| Mental Recall | 1 | 2002 | 1192 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2003 | 1136 | 0.030 |
Why?
|
| Age of Onset | 1 | 2001 | 3316 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 11940 | 0.030 |
Why?
|
| Aspirin | 1 | 2006 | 3190 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 19537 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2004 | 3580 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2005 | 10499 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2003 | 39300 | 0.020 |
Why?
|
| Alleles | 1 | 2002 | 7099 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 7960 | 0.020 |
Why?
|
| Mortality | 1 | 2001 | 2837 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2004 | 4057 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2001 | 2030 | 0.020 |
Why?
|
| Sex Factors | 1 | 2003 | 10666 | 0.020 |
Why?
|
| Health Personnel | 1 | 2002 | 3045 | 0.020 |
Why?
|
| Genotype | 1 | 2002 | 12919 | 0.020 |
Why?
|
| Prognosis | 1 | 2006 | 29005 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 56226 | 0.020 |
Why?
|
| Adolescent | 1 | 2011 | 85155 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 24798 | 0.010 |
Why?
|
| Pregnancy | 1 | 2002 | 27398 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 17409 | 0.010 |
Why?
|